|  |
| --- |
| Pharmacy and Therapeutics Committee Virtual MeetingJanuary 25, 202312:00 PM - 5:00 PM**Zoom Meeting Registration:**To attend the meeting from a PC, Mac, iPad, iPhone, or Android device, please click on the link below:https://ahcccs.zoom.us/s/84698091464?pwd=SjAwYlVWWkZrT0hJK0lEWGZ5Sis4UT09 |
| **Time** | **Topic** |
| **12:00 PM** | **Welcome and Introductions:** Suzanne Berman, RPH, AHCCCS Pharmacy Director**P&T October 19, 2022 - Minutes Review and Vote** |
| **12:15 PM** | **Drug Utilization Initiatives for the CMS Drug Utilization Review Report –** **Amanda Kiriakopoulos, PharmD - OptumRx** |
| **12:45 PM** | **Nineteen Non-Supplemental Rebate Class Reviews:**   1. Androgenic Agents – Hind Douiki, PharmD, Magellan
	1. Public Testimony: None
2. Antidepressants, Others - Hind Douiki, PharmD, Magellan
	1. Public Testimony: None
3. Antidepressants, SSRIs - Hind Douiki, PharmD, Magellan
	1. Public Testimony: None
4. Antivirals – Topical - Hind Douiki, PharmD, Magellan
	1. Public Testimony: None
5. Bone Resorption Suppression Agents - Hind Douiki, PharmD, Magellan
	1. Public Testimony: None
6. Bronchodilators, Beta Agonists - Hind Douiki, PharmD, Magellan
	1. Public Testimony: None
7. Colony Stimulating Factors - Hind Douiki, PharmD, Magellan
	1. Public Testimony: None
8. Enzyme Replacement, Gaucher Disease - Hind Douiki, PharmD, Magellan
	1. Public Testimony: None
9. Erythropoiesis Stimulating Proteins - Hind Douiki, PharmD, Magellan
	1. Public Testimony: None
10. Hypoglycemics, Alpha-Glucosidase Inhibitors - Hind Douiki, PharmD, Magellan
	1. Public Testimony: None
11. Hypoglycemics, Metformins – Jonas Terry, PharmD, Magellan
	1. Public Testimony: None
12. Hypoglycemics, SGLT2s - Jonas Terry, PharmD, Magellan
	1. Public Testimony: None
13. Immune Globulins - Jonas Terry, PharmD, Magellan
	1. Public Testimony: None
14. Oral Oncology, Oral, Hematologic - Brand/Generic - Jonas Terry, PharmD, Magellan
	1. Public Testimony:
15. Ophthalmics, Anti-Inflammatory Products - Jonas Terry, PharmD, Magellan
	1. Public Testimony: None
16. Otic Antibiotics - Jonas Terry, PharmD, Magellan
	1. Public Testimony: None
17. Pulmonary Atrial Hypertension (PAH) Oral and Inhaled Agents - Jonas Terry, PharmD, Magellan
	1. Public Testimony: None
18. Thrombopoiesis Stimulating Proteins - Jonas Terry, PharmD, Magellan
	1. Public Testimony: None
19. Ulcerative Colitis Agents - Jonas Terry, PharmD, Magellan
	1. Public Testimony: None
 |
| **2:10 PM** | **New Drug Reviews:** Hind Douiki, PharmD, Magellan

|  |  |  |
| --- | --- | --- |
| ***Brand Name*** | ***Generic Name*** | ***Drug Class*** |
| **Sotyktu** **Rolvedon SubQ****Sulenca Oral & SubQ** | **Deucravacitinib****Eflapegastim-xnst****Lenacapavir** | **Cytokine and CAM Antagonist****Colony Stimulating Factors****HIV-AIDS** |

 |
| **2:20 PM** | **P&T Requests****Preferred Drug Additions:** Suzi Berman* **Pregabalin**
* **Lithium**

**Step Therapy Removal:** Suzi Berman* **Symbicor**
* **Dulera**
* **Advair**
 |
| **2:30 PM**  | **Break & Executive Session –** Kristen Haloski**,** PharmD, AAHIVP, Magellan |
| **4:00 PM** | **Public Therapeutic Class Votes – Hind Douiki**, PharmD, Magellan |
| **4:25 PM** | **Biosimilar Update: None** |
| **4:30 PM** | **Meeting Adjournment**Future Meeting Dates: May 23, 2023, October 25, 2023 |